Lunit has partnered with Fujifilm Thailand and Microsoft to bring its AI radiology solutions to Bumrungrad International Hospital, a private hospital based in Bangkok.
According to a press statement, Lunit is deploying its chest x-ray analysis software INSIGHT CXR and mammography tool INSIGHT MMG in the hospital.
Together with Fujifilm Thailand, Lunit will supply its AI solutions to Bumrungrad using Microsoft Azure, which the company claims will enhance the operation of its software.
WHY IT MATTERS
Bumrungrad is one of the largest private hospitals in Southeast Asia with 580 beds, serving over a million patients each year across 190 countries.
The hospital aims to provide better services through its timely detection of chest abnormalities and breast cancer using AI.
“AI would be a support tool for human decision-making, providing a second opinion for doctors’ consideration during the diagnostic process,” said Dr Teeradache Viangteeravat, Bumrungrad’s R&D director.
Presently, the hospital is using the Lunit AI solutions in its check-ups, intensive care units, and emergency rooms. The INSIGHT CXR and INSIGHT MMG have so far analysed more than 100,000 images taken each year in the hospital.
Bumrungrad also expects that the AI solutions will help “speed up the learning curve for junior doctors with less experience in reading images”.
Lunit said it plans to support Bumrungrad further to “drive groundbreaking medical innovation across Southeast Asia”.
THE LARGER TREND
Early this year, a similar deployment deal was signed between Lunit and Egypt-based Bahia Foundation. The non-profit charity group, which provides free-of-charge care for breast cancer patients, has adopted the Lunit INSIGHT MMG.
In other news, Lunit recently got its chest x-ray and mammography solutions cleared for market release in Canada. This followed the approval of the US Food and Drug Administration for the same AI products last year.
Last month, Lunit filed a registration statement with the Korean Exchange for an initial public offering this July. The company plans to issue a total of 1.12 million shares worth between $34-$38 apiece.